Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

52.79 +0.51 (+0.98%)
Streaming Delayed Price Updated: 3:06 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
Analyzing Sanofi's Short Interest
Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of... 
Via Benzinga
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis. 
Via InvestorPlace
Daily Stock Analysis: Sanofi S.A.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris. 
Via Talk Markets
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients
Via Benzinga
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold
The company was testing the drug in multiple sclerosis and myasthenia gravis. 
Via Investor's Business Daily
Why Sanofi Shares Are Falling Today
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Via Benzinga
Sanofi Offloads 17 Products To Neuraxpharm
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.  
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Via Benzinga
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
This New York-Based Digital Therapeutics Company Looks To Disrupt a $475 Billion Market
As the global coronavirus pandemic forced people to keep their distance from one another, there has been an increase in the adoption of digital health solutions among healthcare professionals and... 
Via Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
How Is The Market Feeling About Sanofi?
Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,... 
Via Benzinga
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients
Via Benzinga
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
The companies' shot was more than 93% effective in previously infected people. 
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Reuters 
Via Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc. 
Via Benzinga
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session. 
Via InvestorPlace
Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors
Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.